Busulfan clearance in renal failure and hemodialysis

Bone Marrow Transplantation

Volumn 25, Issue 2, 2000, Pages 201-203

  Ullery, L L ^a,b   Gibbs, J P ^b   Ames, G W ^a   Senecal, F M ^a   Slattery, J T ^b,c  

^a St Joseph Hospital Tacoma   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

Author keywords

Busulfan; Chronic renal failure; Clearance; Hemodialysis; Lymphoma

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PROCARBAZINE;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LEUKAPHERESIS; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0033951895     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702112     Document Type: Article

References (11)

1. 14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokin 1987; 12: 71-76.
2. Hassan M, Oberg G, Ehrsson H et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525-530.
3. Marchand DH, Remmel RP, Abdel-Monem MM, Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat. Drug Metab Disp 1988; 16: 85-92.
4. Gibbs JP, Czerwinski M, Slattery JF. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996; 56: 3678-3681.
5. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Disp 1996; 24: 1015-1019.
6. Beckett GJ, Hayes JD. Glutathione S-transferases: biomedical applications. Adv Clin Chem 1993; 30: 281-380.
7. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
8. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Williams and Wilkins: Philadelphia, 1995, p 443.
9. Bishop JB, Wassom JS. Toxicological review of busulfan (myleran). Mut Res 1986; 168: 15-45.
10. Gibbs J, Gooley T, Murray G et al. The impact of obesity and disease on the oral clearance of busulfan in adults. Blood 1999; 93: 4436-4440.
11. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chem Pharmacol 1989; 25: 55-61.